Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $33.0 million.

  • Janux Therapeutics' Share-based Compensation fell 41.22% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 18.25%. This contributed to the annual value of $33.0 million for FY2024, which is 65.06% up from last year.
  • Janux Therapeutics' Share-based Compensation amounted to $33.0 million in FY2024, which was up 65.06% from $20.0 million recorded in FY2023.
  • Over the past 5 years, Janux Therapeutics' Share-based Compensation peaked at $33.0 million during FY2024, and registered a low of $72,000 during FY2020.
  • For the 3-year period, Janux Therapeutics' Share-based Compensation averaged around $23.4 million, with its median value being $20.0 million (2023).
  • Data for Janux Therapeutics' Share-based Compensation shows a peak YoY spiked of 9,497.22% (in 2021) over the last 5 years.
  • Over the past 5 years, Janux Therapeutics' Share-based Compensation (Yearly) stood at $72,000 in 2020, then surged by 9,497.22% to $6.9 million in 2021, then surged by 148.96% to $17.2 million in 2022, then climbed by 16.29% to $20.0 million in 2023, then spiked by 65.06% to $33.0 million in 2024.